Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 19203586 
Kawase T, et al. (2009) PH domain-only protein PHLDA3 is a p53-regulated repressor of Akt. Cell 136, 535-50 19203586
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

T308-p - Akt1 (human)
Orthologous residues
Akt1 (human): T308‑p, Akt1 (mouse): T308‑p, Akt1 (rat): T308‑p, Akt1 (fruit fly): T423‑p, Akt1 (cow): T308‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  bone cancer, breast cancer, breast adenocarcinoma, breast cancer, triple negative, prostate cancer
 Relevant cell lines - cell types - tissues:  LNCaP (prostate cell), MCF-7 (breast cell), MDA-MB468 (breast cell), U2OS (bone cell), WI-38 (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
Phlda3 (human) decrease
p53 (human) decrease

S473-p - Akt1 (human)
Orthologous residues
Akt1 (human): S473‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  bone cancer, breast cancer, breast adenocarcinoma, breast cancer, triple negative, prostate cancer
 Relevant cell lines - cell types - tissues:  LNCaP (prostate cell), MCF-7 (breast cell), MDA-MB468 (breast cell), U2OS (bone cell), WI-38 (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
Phlda3 (human) decrease
p53 (human) decrease
p53 (human), Phlda3 (human) decrease Phlda3 shRNA increase
Phlda3 (human) decrease Phlda3 shRNA increase
adriamycin decrease
adriamycin Phlda3 (human) decrease Phlda3 siRNA increase

T202-p - ERK1 (human)
Orthologous residues
ERK1 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  bone cancer, breast cancer, breast adenocarcinoma, breast cancer, triple negative, prostate cancer
 Relevant cell lines - cell types - tissues:  LNCaP (prostate cell), MCF-7 (breast cell), MDA-MB468 (breast cell), U2OS (bone cell), WI-38 (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
Phlda3 (human) no change compared to control Phlda3 siRNA no change
p53 (human) increase

Y204-p - ERK1 (human)
Orthologous residues
ERK1 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  bone cancer, breast cancer, breast adenocarcinoma, breast cancer, triple negative, prostate cancer
 Relevant cell lines - cell types - tissues:  LNCaP (prostate cell), MCF-7 (breast cell), MDA-MB468 (breast cell), U2OS (bone cell), WI-38 (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
Phlda3 (human) no change compared to control Phlda3 siRNA no change
p53 (human) increase

T185-p - ERK2 (human)
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  bone cancer, breast cancer, breast adenocarcinoma, breast cancer, triple negative, prostate cancer
 Relevant cell lines - cell types - tissues:  LNCaP (prostate cell), MCF-7 (breast cell), MDA-MB468 (breast cell), U2OS (bone cell), WI-38 (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
Phlda3 (human) no change compared to control Phlda3 siRNA no change
p53 (human) increase

Y187-p - ERK2 (human)
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  bone cancer, breast cancer, breast adenocarcinoma, breast cancer, triple negative, prostate cancer
 Relevant cell lines - cell types - tissues:  LNCaP (prostate cell), MCF-7 (breast cell), MDA-MB468 (breast cell), U2OS (bone cell), WI-38 (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
Phlda3 (human) no change compared to control Phlda3 siRNA no change
p53 (human) increase

S166-p - MDM2 (human)
Orthologous residues
MDM2 (human): S166‑p, MDM2 iso12 (human): , MDM2 (mouse): S163‑p, MDM2 (rat): S138‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  bone cancer, breast cancer, breast adenocarcinoma, breast cancer, triple negative, prostate cancer
 Relevant cell lines - cell types - tissues:  LNCaP (prostate cell), MCF-7 (breast cell), MDA-MB468 (breast cell), U2OS (bone cell), WI-38 (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
Phlda3 (human) decrease Phlda3 siRNA increase

S15-p - p53 (human)
Orthologous residues
p53 (human): S15‑p, p53 (mouse): S15‑p, p53 iso2 (mouse): S18‑p, p53 (rat): S15‑p, p53 (rabbit): S15‑p, p53 (monkey): S15‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  bone cancer, breast cancer, breast adenocarcinoma, breast cancer, triple negative, prostate cancer
 Relevant cell lines - cell types - tissues:  LNCaP (prostate cell), MCF-7 (breast cell), MDA-MB468 (breast cell), U2OS (bone cell), WI-38 (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
UV increase
ionizing radiation increase
caffeine ionizing radiation inhibit treatment-induced increase
ionizing radiation ATM (human) increase ATM siRNA inhibits
Downstream Regulation
 Effect of modification (process):  transcription, induced
 Comments:  full activation of Phlda3 promoter


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.